[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Alto Development Corp\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":118},{"warningLetters":4,"total":117},[5,32,54,75,96],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":31,"medical_device_id":20,"response_letter_date":20},1407,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-06-25T04:00:00Z\">06\u002F25\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-21T04:00:00Z\">06\u002F21\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffrozen-food-development-inc-673836-06212024\">Frozen Food Development, Inc. \u003C\u002Fa>","Division of Human and Animal Food Operations East II","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated\u003Cbr \u002F>\r\n","","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gary H. Gregory\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Frozen Food Development, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>156 W. Harrisburg Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Elizabethtown\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>17570\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations East II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 673836\u003C\u002Fp>\u003Cp>June 21, 2024\u003C\u002Fp>\u003Cp>Dear Mr. Gregory:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your individually quick frozen (IQF) packing and re-packing ready-to-eat (RTE) fruits and vegetables facility located at 156 W. Harrisburg Avenue, Elizabethtown, PA between October 10 and 13, 2023, and on November 30, 2023. During our inspection, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\u003C\u002Fp>\u003Cp>Based on FDA’s inspectional findings, we have determined that the IQF RTE fruits and vegetables packed and re-packed in your facility are adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that they were prepared, packed, or held un-der insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive control provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by Section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and FDA’s regulations through links in FDA’s home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations, to Matt C. Rinehart, Operations Manager. We received your response sent via email on December 22, 2023, which included a summary of corrective actions you have taken or plan to take to address the observa-tions listed on the FDA-483. After reviewing the inspectional findings and the response your firm provided, we are issuing this letter to advise you of FDA’s concern and provide detailed information describing the findings at your facility. We also address your responses below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Current Good Manufacturing Practice (21 CFR Part 117, Subpart B)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>1. You did not take effective measures to exclude pests from your holding areas and to protect against contamination of food and food-packaging materials on the premises by pests, as required by 21 CFR Part 117.35(c).\u003C\u002Fp>\u003Cp>Specifically, October 11, 2023, the FDA investigator observed evidence of rodent activity, including apparent rodent excreta pellets (REP) in numbers too numerous to count in the following areas of your facility:\u003C\u002Fp>\u003Cul>\u003Cli>On the floor and along the walls of the \u003Cstrong>(b)(4) \u003C\u002Fstrong>warehouse and related storage areas, where direct food-contact packaging materials (intended for frozen RTE produce) were stored.\u003C\u002Fli>\u003Cli>On the floor in Freezers \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In \u003Cstrong>(b)(4)\u003C\u002Fstrong>, exposed bulk chickpeas (lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>) were being held prior to being packaged. In Freezer \u003Cstrong>(b)(4)\u003C\u002Fstrong>, exposed RTE bulk strawberries (lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>) were being held prior to being packaged.\u003C\u002Fli>\u003Cli>Along the wall in Freezer \u003Cstrong>(b)(4)\u003C\u002Fstrong> and within approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> inches of Market Basket Mixed Fruit (lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>), which was being stored, partially exposed, and awaiting use in production.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>There was a previous FDA inspection conducted December 13, 2021 through March 7, 2022. That inspection also revealed failure to exclude pests from your facility, as evidenced by REPs and dead rodents.\u003C\u002Fp>\u003Cp>In your written response, dated December 22, 2023, you stated that you plan to immediately clean up the REPs and dispose of affected products. You also stated that your facility had a pest problem in 2021 and that you retained a different pest company in early 2022, which has helped in “reducing the number of pests entering your facility”. You stated that this recent improvement is “reflected in your logs in the com-parison from the first FDA visit in 2021”. Additionally, gaps in the walls and other building damage contrib-ute to pests entering the facility. However, your response did not describe how you have or plan to exclude pests from accessing your facility going forward (such as making building repairs in response to the most recent inspection).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Hazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>2. You did not establish and implement a risk-based supply-chain program for those raw materials and other ingredients for which you have identified a hazard needing a supply-chain-applied con-trol, as required by 21 CFR 117.405(a)(1).\u003C\u002Fp>\u003Cp>Specifically, your hazard analyses, dated January 18, 2023 and October 16, 2023, titled “Hayssen 1”, “Hayssen 2”, and “PPI”, for your frozen RTE produce indicate that pathogens are a hazard re-quiring a preventive control. The frozen RTE produce you receive is not treated to destroy patho-gens before leaving your facility. Your hazard analyses also indicate that pathogens on incoming frozen RTE produce will be controlled through “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, vegetative bacterial pathogens such as L. monocytogenes and Salmo-nella in RTE produce constitute a hazard that can cause serious adverse health consequences or death and thus annual onsite audit is the appropriate supplier verification activity unless there is a written determination that other verification activities and\u002For less frequent onsite auditing of supplier provide adequate assurance that the hazard is controlled (see 21 CFR 117.430(b)). The audit must be conducted before using the raw material or other ingredient from the supplier and at least annu-ally thereafter (see 21 CFR 117.430(b)(1)(ii)).\u003C\u002Fp>\u003Cp>The previous FDA inspection conducted December 13, 2021 to March 7, 2021, similarly revealed failure to provide evidence that results of supplier audits were reviewed to verify control of vegeta-tive bacterial pathogens.\u003C\u002Fp>\u003Cp>In your written response, dated December 22, 2023, you stated that you will review COA’s, Supplier Certificates and Supplier Audits to ensure control for pathogens in frozen RTE produce that you receive from your suppliers. However, you did not submit a revised hazard analysis or revised supply-chain program clarifying the specific supplier verification activities required for the vegetative bacterial pathogen hazard.\u003C\u002Fp>\u003Cp>3. You did not identify and evaluate a known or reasonably foreseeable hazard to determine whether it is a hazard requiring a preventive control, as required by 21 CFR Part 117.130(a)(1).\u003C\u002Fp>\u003Cp>Specifically, you did not identify and evaluate Cyclospora as a known or reasonably foreseeable hazard to determine whether it requires a preventive control in your frozen RTE berry products. Your hazard analyses titled “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” dated January 18, 2023, for pro-cessing frozen RTE produce (including berries) did not consider the parasite Cyclospora, which has been associated with frozen RTE berries. Oocysts of Cyclospora can be shed by infected hosts during harvesting. Depending on time and temperature, freezing may not be effective in ap-propriately destroying Cyclospora. Your berries are not treated to destroy pathogens before leaving your facility. A knowledgeable person processing food in your circumstances would identify Cyclo-spora as a hazard requiring a preventive control (i.e., supply-chain control) in the frozen RTE ber-ries you receive. Supply-chain controls include a supply-chain program as required by Subpart G of 21 CFR Part 117.\u003C\u002Fp>\u003Cp>In addition, during the inspection, your quality manager stated that while reviewing audit results, she did not evaluate whether the audits specifically covered good agricultural practices and ade-quate water sources at the grower level [e.g., the most recent audit data for Healthy Frozen Inc (a freezing facility in Weston, FL from which you receive frozen RTE blackberries)]. You did not review Healthy Frozen Inc.’s supply-chain controls associated with the Cyclospora hazard at the farm.\u003C\u002Fp>\u003Cp>The previous FDA inspection conducted December 13, 2021 through March 7, 2022, also revealed failure to identify Cyclospora as a known or reasonably foreseeable hazard to determine whether it requires a preventive control for frozen RTE berries.\u003C\u002Fp>\u003Cp>During the most recent inspection, you provided an updated food safety plan dated October 16, 2023, concluding that Cyclospora is a hazard requiring a preventive control in the three hazard analyses noted above. In your written response, dated December 22, 2023, you stated that you added Cyclospora as a hazard in your food safety plan and that you will review COA’s, Supplier Certificates, and Supplier Audits. You also stated that you will review all audits, including the testing of water sources, to determine whether your suppliers are controlling Cyclospora. However, you did not include a revised supply-chain program in your updated food safety plan, nor did you submit one with your response. You also did not describe how you will verify control of practices and conditions to significantly minimize or prevent Cyclospora contamination of RTE berries at the grower level (e.g., effective hand washing; preventing human feces in latrines from entering the field through, for example, latrine tips and spills, or contamination of boots; worker health; and cleanliness of food-contact surfaces). Furthermore, you did not provide records demonstrating that you have implemented your corrective actions and have addressed employee training specific to these updates.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to ade-quately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\u003Cp>In addition to the violations described above, we offer the following comment:\u003C\u002Fp>\u003Cul>\u003Cli>We note that your food safety plan lists Norovirus as a known hazard for produce. However, your hazard analyses titled “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” dated October 16, 2023, for processing frozen RTE produce (including berries) did not evaluate whether viruses such as Norovirus and Hepatitis A require a preventive control. You should include viruses in your hazard analyses and determine whether they are a significant hazard in your frozen RTE produce.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written response should be sent to Compliance Officer Melissa B. Libby at U.S. Food &amp; Drug Admin-istration, 10 Waterview Blvd., 3rd Floor, Parsippany, NJ 07054. An emailed response is also acceptable. Files greater than 100 megabytes may be submitted as smaller files in separate emails. If you have ques-tions regarding this letter, please contact Melissa Libby by telephone at (973) 331-4997 or by email at melissa.libby@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F&nbsp;\u003Cbr>Robin M. Rivers&nbsp;&nbsp;\u003Cbr>Acting Program Division Director\u003Cbr>Baltimore District Office&nbsp;&nbsp;\u003Cbr>Human &amp; Animal Food East, Division 2&nbsp;&nbsp;\u003Cbr>Office of Regulatory Affairs&nbsp;&nbsp;\u003Cbr>U.S. Food and Drug Administration&nbsp;&nbsp;\u003Cbr>randy.pack@fda.hhs.gov\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nGary H. Gregory\n\nRecipient Title\n\nPresident\n\nFrozen Food Development, Inc.\n\n156 W. Harrisburg Avenue\n\nElizabethtown, PA 17570\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East II\n\nUnited States\n\nWARNING LETTER\nCMS # 673836\nJune 21, 2024\nDear Mr. Gregory:\nThe United States Food and Drug Administration (FDA) inspected your individually quick frozen (IQF) packing and re-packing ready-to-eat (RTE) fruits and vegetables facility located at 156 W. Harrisburg Avenue, Elizabethtown, PA between October 10 and 13, 2023, and on November 30, 2023. During our inspection, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\nBased on FDA’s inspectional findings, we have determined that the IQF RTE fruits and vegetables packed and re-packed in your facility are adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that they were prepared, packed, or held un-der insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive control provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by Section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and FDA’s regulations through links in FDA’s home page at http:\u002F\u002Fwww.fda.gov.\nAt the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations, to Matt C. Rinehart, Operations Manager. We received your response sent via email on December 22, 2023, which included a summary of corrective actions you have taken or plan to take to address the observa-tions listed on the FDA-483. After reviewing the inspectional findings and the response your firm provided, we are issuing this letter to advise you of FDA’s concern and provide detailed information describing the findings at your facility. We also address your responses below.\nCurrent Good Manufacturing Practice (21 CFR Part 117, Subpart B)\n1. You did not take effective measures to exclude pests from your holding areas and to protect against contamination of food and food-packaging materials on the premises by pests, as required by 21 CFR Part 117.35(c).\nSpecifically, October 11, 2023, the FDA investigator observed evidence of rodent activity, including apparent rodent excreta pellets (REP) in numbers too numerous to count in the following areas of your facility:\nOn the floor and along the walls of the (b)(4) warehouse and related storage areas, where direct food-contact packaging materials (intended for frozen RTE produce) were stored.\nOn the floor in Freezers (b)(4). In (b)(4), exposed bulk chickpeas (lot #(b)(4)) were being held prior to being packaged. In Freezer (b)(4), exposed RTE bulk strawberries (lot #(b)(4)) were being held prior to being packaged.\nAlong the wall in Freezer (b)(4) and within approximately (b)(4) inches of Market Basket Mixed Fruit (lot #(b)(4)), which was being stored, partially exposed, and awaiting use in production.\nThere was a previous FDA inspection conducted December 13, 2021 through March 7, 2022. That inspection also revealed failure to exclude pests from your facility, as evidenced by REPs and dead rodents.\nIn your written response, dated December 22, 2023, you stated that you plan to immediately clean up the REPs and dispose of affected products. You also stated that your facility had a pest problem in 2021 and that you retained a different pest company in early 2022, which has helped in “reducing the number of pests entering your facility”. You stated that this recent improvement is “reflected in your logs in the com-parison from the first FDA visit in 2021”. Additionally, gaps in the walls and other building damage contrib-ute to pests entering the facility. However, your response did not describe how you have or plan to exclude pests from accessing your facility going forward (such as making building repairs in response to the most recent inspection).\nHazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C)\n2. You did not establish and implement a risk-based supply-chain program for those raw materials and other ingredients for which you have identified a hazard needing a supply-chain-applied con-trol, as required by 21 CFR 117.405(a)(1).\nSpecifically, your hazard analyses, dated January 18, 2023 and October 16, 2023, titled “Hayssen 1”, “Hayssen 2”, and “PPI”, for your frozen RTE produce indicate that pathogens are a hazard re-quiring a preventive control. The frozen RTE produce you receive is not treated to destroy patho-gens before leaving your facility. Your hazard analyses also indicate that pathogens on incoming frozen RTE produce will be controlled through “(b)(4).” However, vegetative bacterial pathogens such as L. monocytogenes and Salmo-nella in RTE produce constitute a hazard that can cause serious adverse health consequences or death and thus annual onsite audit is the appropriate supplier verification activity unless there is a written determination that other verification activities and\u002For less frequent onsite auditing of supplier provide adequate assurance that the hazard is controlled (see 21 CFR 117.430(b)). The audit must be conducted before using the raw material or other ingredient from the supplier and at least annu-ally thereafter (see 21 CFR 117.430(b)(1)(ii)).\nThe previous FDA inspection conducted December 13, 2021 to March 7, 2021, similarly revealed failure to provide evidence that results of supplier audits were reviewed to verify control of vegeta-tive bacterial pathogens.\nIn your written response, dated December 22, 2023, you stated that you will review COA’s, Supplier Certificates and Supplier Audits to ensure control for pathogens in frozen RTE produce that you receive from your suppliers. However, you did not submit a revised hazard analysis or revised supply-chain program clarifying the specific supplier verification activities required for the vegetative bacterial pathogen hazard.\n3. You did not identify and evaluate a known or reasonably foreseeable hazard to determine whether it is a hazard requiring a preventive control, as required by 21 CFR Part 117.130(a)(1).\nSpecifically, you did not identify and evaluate Cyclospora as a known or reasonably foreseeable hazard to determine whether it requires a preventive control in your frozen RTE berry products. Your hazard analyses titled “(b)(4)”, “(b)(4)”, and “(b)(4)” dated January 18, 2023, for pro-cessing frozen RTE produce (including berries) did not consider the parasite Cyclospora, which has been associated with frozen RTE berries. Oocysts of Cyclospora can be shed by infected hosts during harvesting. Depending on time and temperature, freezing may not be effective in ap-propriately destroying Cyclospora. Your berries are not treated to destroy pathogens before leaving your facility. A knowledgeable person processing food in your circumstances would identify Cyclo-spora as a hazard requiring a preventive control (i.e., supply-chain control) in the frozen RTE ber-ries you receive. Supply-chain controls include a supply-chain program as required by Subpart G of 21 CFR Part 117.\nIn addition, during the inspection, your quality manager stated that while reviewing audit results, she did not evaluate whether the audits specifically covered good agricultural practices and ade-quate water sources at the grower level [e.g., the most recent audit data for Healthy Frozen Inc (a freezing facility in Weston, FL from which you receive frozen RTE blackberries)]. You did not review Healthy Frozen Inc.’s supply-chain controls associated with the Cyclospora hazard at the farm.\nThe previous FDA inspection conducted December 13, 2021 through March 7, 2022, also revealed failure to identify Cyclospora as a known or reasonably foreseeable hazard to determine whether it requires a preventive control for frozen RTE berries.\nDuring the most recent inspection, you provided an updated food safety plan dated October 16, 2023, concluding that Cyclospora is a hazard requiring a preventive control in the three hazard analyses noted above. In your written response, dated December 22, 2023, you stated that you added Cyclospora as a hazard in your food safety plan and that you will review COA’s, Supplier Certificates, and Supplier Audits. You also stated that you will review all audits, including the testing of water sources, to determine whether your suppliers are controlling Cyclospora. However, you did not include a revised supply-chain program in your updated food safety plan, nor did you submit one with your response. You also did not describe how you will verify control of practices and conditions to significantly minimize or prevent Cyclospora contamination of RTE berries at the grower level (e.g., effective hand washing; preventing human feces in latrines from entering the field through, for example, latrine tips and spills, or contamination of boots; worker health; and cleanliness of food-contact surfaces). Furthermore, you did not provide records demonstrating that you have implemented your corrective actions and have addressed employee training specific to these updates.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to ade-quately address this matter may result in legal action including, without limitation, seizure, and injunction.\nIn addition to the violations described above, we offer the following comment:\nWe note that your food safety plan lists Norovirus as a known hazard for produce. However, your hazard analyses titled “(b)(4)”, “(b)(4)”, and “(b)(4)” dated October 16, 2023, for processing frozen RTE produce (including berries) did not evaluate whether viruses such as Norovirus and Hepatitis A require a preventive control. You should include viruses in your hazard analyses and determine whether they are a significant hazard in your frozen RTE produce.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written response should be sent to Compliance Officer Melissa B. Libby at U.S. Food & Drug Admin-istration, 10 Waterview Blvd., 3rd Floor, Parsippany, NJ 07054. An emailed response is also acceptable. Files greater than 100 megabytes may be submitted as smaller files in separate emails. If you have ques-tions regarding this letter, please contact Melissa Libby by telephone at (973) 331-4997 or by email at melissa.libby@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nRobin M. Rivers\nActing Program Division Director\nBaltimore District Office\nHuman & Animal Food East, Division 2\nOffice of Regulatory Affairs\nU.S. Food and Drug Administration\nrandy.pack@fda.hhs.gov","Frozen Food Development, Inc.","frozen-food-development-inc-673836-06212024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffrozen-food-development-inc-673836-06212024","2026-10-26T08:08:43.774134+00:00","Warning Letter","Issued","2024-06-25","673836","Food & Beverages","Gary H. Gregory","2026-08-20T00:00:33.341+00:00","VIA UPS","2024-06-21",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":20,"letter_url":45,"updated_at":46,"action_type":23,"case_status":24,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":20,"issuing_office":38,"recipient_name":50,"body_fetched_at":51,"delivery_method":30,"recipient_title":20,"reference_number":52,"action_taken_date":53,"medical_device_id":20,"response_letter_date":20},420,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2025-12-16T05:00:00Z\">12\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-04T05:00:00Z\">12\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F3d-imaging-drug-design-and-development-llc-716213-12042025\">3D Imaging Drug Design and Development LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FPositron Emission Tomography (PET) Drugs\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-23\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Marc S. Berridge, Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>3D Imaging Drug Design and Development LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9015 Carti Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Little Rock\u003C\u002Fspan>, \u003Cspan>AR\u003C\u002Fspan> \u003Cspan>72205\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-23\u003C\u002Fp>\u003Cp>December 4, 2025\u003C\u002Fp>\u003Cp>Dear Dr. Berridge:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, 3D Imaging Drug Design and Development LLC, FEI 3009143510, at 9015 Carti Way, Little Rock, from June 9 to 13, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for positron emission tomography (PET) drugs. See Title 21 Code of Federal Regulations (CFR), part 212 (21 CFR part 212).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packaging, or holding do not conform to CGMP, your PET drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, we reviewed your firm’s drug listing submissions in FDA’s electronic Drug Registration and Listing System (eDRLS) and found that you failed to update the listing for your PET human prescription drug product, Fludeoxyglucose F18 (NDC 76451-118), as required under section 510(j) of the FD&amp;C Act (21 U.S.C. 360(j)) and 21 CFR part 207.\u003C\u002Fp>\u003Cp>Thus, Fludeoxyglucose F18 is not properly listed, and your firm has not fulfilled its listing obligations under 510(j) of the FD&amp;C Act (21 U.S.C. 360(j)) and 21 CFR 207, which is prohibited under section 301(p) of the FD&amp;C Act (21 U.S.C. 331(p)). This violation is described in more detail below.\u003C\u002Fp>\u003Cp>We reviewed your June 30, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your facilities are not adequate to ensure the prevention of contamination of equipment or product by substances, personnel, or environmental conditions that could reasonably be expected to have an adverse effect on product quality. Procedures to ensure that all equipment is clean, suitable for its intended purposes, properly installed, maintained, and capable of repeatedly producing valid results, are not adequately followed (21 CFR 212.30(a) and (b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Facility Suitability\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to ensure that your facility is adequately designed and controlled to prevent contamination of the sterile injectable PET drugs you manufacture. For example, our investigator observed your operator making aseptic connections in an open benchtop area, without adequate aseptic environmental conditions. Furthermore, our investigator observed that Hot Cell #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is used to manufacture Fludeoxyglucose F-18 (FDG), was in a poor state of repair, with rust on the manipulator arms and with visible residue on surfaces near where the finished product is filtered into sterile vials.\u003C\u002Fp>\u003Cp>In your response, you state that you made facility and equipment repairs, including removal of rust and replacement of the chipped lead shielding in your hot cell. Your response is inadequate because you do not evaluate your facility, process, and equipment for potential routes of contamination or address how you will improve your process to ensure that your product is properly protected from the environment during aseptic connections.\u003C\u002Fp>\u003Cp>Appropriate aseptic environments should be used for critical aseptic manipulation in the production and testing of PET drugs.\u003C\u002Fp>\u003Cp>\u003Cem>Environmental Monitoring\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to establish and follow adequate testing procedures for environmental monitoring (EM) for your aseptic manufacturing area. For example, your Hot Cell #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, where the FDG drug product is filtered into the final product vials, is not monitored. Further, the alert and action levels that you established in your standard operating procedure (“SOP for Environmental Monitoring of Hot Cells”) for EM are not appropriate. For surface samples taken in your hot cell, your procedure does not require an investigation unless \u003Cstrong>(b)(4)\u003C\u002Fstrong> or more colony-forming units are recovered from a single sample. Your high action levels allow for an unacceptable risk of contamination to your product.\u003C\u002Fp>\u003Cp>In your response, you indicate that you lack an understanding of where the environmental monitoring should occur, and that you will update your EM to include a location “adjacent to the sterile closure.” Your response is inadequate because you do not address how you will determine the appropriate sampling location and frequency for EM.\u003C\u002Fp>\u003Cp>PET drug products have short expiry periods. Thus, your PET drug products are released and administered before the results of batch specific sterility testing and EM are known. Therefore, adequate microbiological monitoring of the aseptic environment is essential during critical aseptic manipulation. A vigilant, ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes but is not limited to:\u003Cbr>o All human interactions within the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> area\u003Cbr>o Equipment placement and ergonomics\u003Cbr>o Air quality in the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> area and surrounding room\u003Cbr>o Facility layout\u003Cbr>o Personnel flows and material flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\u003Cli>Your updated procedure(s) demonstrating that aseptic connections will be conducted in an appropriate environment (e.g., ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> aseptic workstation).\u003C\u002Fli>\u003Cli>An independent assessment of your EM program, including but not limited to establishing appropriate limits, sampling locations and frequencies, investigating deviations, and trend analysis, and a comprehensive corrective action and preventive action plan.\u003C\u002Fli>\u003Cli>Your action levels for ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> surfaces, air, and operator gloves, and revised procedures that describe the appropriate response to contamination in critical environments.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to have adequate production and process controls to ensure the consistent production of a PET drug that meets the applicable standards of identity, strength, quality, and purity (21 CFR 212.50).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to ensure that your operators are appropriately gowned to adequately protect the sterile injectable PET drugs you manufacture. For example, our investigator observed exposed skin and hair on your operator during the manufacturing of FDG lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The operators’ skin on their arms was exposed while they were setting up production in an open benchtop area of the room (i.e. with inadequate aseptic environmental conditions). The operators’ skin was also exposed while leaning into Hot Cell #\u003Cstrong>(b)(4)\u003C\u002Fstrong> to set up for product \u003Cstrong>(b)(4)\u003C\u002Fstrong> into sterile vials. Additionally, another operator was observed reaching into the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> laminar flow hood with exposed skin on the operator’s arms and face while performing sterility testing for FDG lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Furthermore, you failed to adequately requalify two of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> operators at least annually by conducting a media fill to assess their aseptic processing technique. For example, one of your operators had not been requalified to perform PET drug manufacturing using process simulations (media fills) since April 2021. However, the operator manufactured FDG as recently as June 2025.\u003C\u002Fp>\u003Cp>In your response, you indicate that the two operators were removed from production and a media fill was initiated. However, your response is inadequate because you do not provide a retrospective assessment of the potential impact to drug products manufactured from 2021 to present. Your response is also inadequate because you do not comprehensively address how you will ensure that your gowning program is adequate, including whether appropriate gowning will be used.\u003C\u002Fp>\u003Cp>Adequate gowning is an essential part of environmental control because gowns provide a barrier to prevent operators from contaminating the drug product. Personnel should be adequately trained and qualified to ensure their competence to perform aseptic processing of PET drugs.\u003C\u002Fp>\u003Cp>Media fills should simulate the aseptic production process, including but not limited to the aseptic assembly of the container\u002Fclosure system through filling of the PET drug into final containers. Operators should be requalified annually by conducting one media fill run. See FDA’s guidance document \u003Cem>Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F81974\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability and assures that manufacturing operations meet appropriate parameters and quality standards. This includes but is not limited to evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\u003C\u002Fli>\u003Cli>A comprehensive assessment of your gowning program, including but not limited to how you will establish adequate gowning.\u003C\u002Fli>\u003Cli>The report and results for the media fill initiated on June 16, 2025, and any subsequent media fills conducted.\u003C\u002Fli>\u003Cli>A comprehensive assessment of your media fill procedure, including but not limited to how you will ensure that operators are requalified annually.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to have laboratory methods suitable for their intended use and sufficiently sensitive, specific, accurate, and reproducible (21 CFR 212.60).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to establish and follow adequate testing procedures for sterility testing of your sterile injectable PET drugs. For example, our investigator observed your operator performing sterility testing using poor aseptic technique, including opening sterile components outside of the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> laminar flow hood before use. Also, our investigator observed your chemist vigorously shaking the sterility test sample tubes before reading the results. Shaking the sterility test sample tubes may mask the test results and may impact a person’s ability to visually detect turbidity, visible colonies, or other evidence of microorganisms.\u003C\u002Fp>\u003Cp>In your response, you indicate that you updated your sterility testing procedure. However, your response is inadequate because it lacks information about how you will ensure that your procedures are sufficiently detailed for operators to follow and how you will ensure that sterility testing is adequately performed.\u003C\u002Fp>\u003Cp>Testing is a critical control that provides assurance that your PET drug products are sterile and therefore suitable for their intended use. It is important that you follow established, appropriate procedures to ensure that your sterility testing can detect the presence of microorganisms.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A comprehensive assessment of your sterility testing program, including but not limited to material flow and environmental monitoring.\u003C\u002Fli>\u003Cli>A comprehensive review of your sterility testing procedure relative to the expectations in the United States Pharmacopeia (USP) General Chapter &lt;71,&gt; Sterility Tests.\u003C\u002Fli>\u003Cli>Your most recent static and dynamic smoke studies performed for the laminar flow hood.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>Drug Listing Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Section 510(j) of the FD&amp;C Act (21 U.S.C. 360(j)) and 21 CFR part 207 set forth the requirements for the listing of drugs. Under 21 CFR 207.57(b), registrants are required to update drug listing information twice each year, in June and December. Under 21 CFR 207.57(b)(2), registrants may satisfy the listing update requirement with respect to unchanged listing information by making a single “no changes” certification during the October 1 through December 31 annual registration period. If the drug listing data is not updated or certified, the outdated listing data will get inactivated at the next scheduled FDA inactivation period.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> You failed to update or certify Fludeoxyglucose F18 as required.\u003C\u002Fp>\u003Cp>Therefore, Fludeoxyglucose F18 is not properly listed under section 510(j) of the FD&amp;C Act. Failure to properly list a drug in accordance with 510(j) of the FD&amp;C Act is prohibited under section 301(p) of the FD&amp;C Act (21 U.S.C. 331(p)).\u003C\u002Fp>\u003Cp>Complete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply-chain security, and postmarket surveillance. Establishment registration and drug listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\u003Cp>In addition, we note that your drug listings for Ammonia N 13 (NDC 76451-013) and Sodium Fluoride F-18 (NDC 76451-018) also have not been updated or certified. Please update the listing information for these drugs to reflect their current status. If you no longer manufacture and distribute these drugs, then the drugs must be discontinued by adding an end marketing date. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding your drug listings, please contact us at eDRLS@fda.hhs.gov for further assistance.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all drugs manufactured at your establishment comply with all establishment registration and drug listing requirements under section 510 of the FD&amp;C Act, 21 U.S.C. 360, 21 CFR part 207, and all other applicable FDA regulations. Registration and listing information and instructions on how to properly register an establishment or submit drug listings can be found at \u003Cem>Electronic Drug Registration and Listing Instructions\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>\u003Cstrong>Guidance on Positron Emission Tomography (PET) Drugs\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>See FDA’s guidance document, \u003Cem>PET Drugs—Current Good Manufacturing Practice\u003C\u002Fem>, to help you meet the CGMP requirements when manufacturing PET drugs, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71013\u002Fdownload. This guidance document also references FDA’s guidance document, \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> for additional concepts and expectations that may apply to PET drug manufacturing, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009143510 and ATTN: Lynnsey Renn.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See 84 FR 40417 (https:\u002F\u002Fwww.regulations.gov\u002Fdocument\u002FFDA-2019-N-2374-0001).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-23\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMarc S. Berridge, Ph.D.\n\nRecipient Title\n\nPresident\n\n3D Imaging Drug Design and Development LLC\n\n9015 Carti Way\n\nLittle Rock, AR 72205\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-23\nDecember 4, 2025\nDear Dr. Berridge:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, 3D Imaging Drug Design and Development LLC, FEI 3009143510, at 9015 Carti Way, Little Rock, from June 9 to 13, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for positron emission tomography (PET) drugs. See Title 21 Code of Federal Regulations (CFR), part 212 (21 CFR part 212).\nBecause your methods, facilities, or controls for manufacturing, processing, packaging, or holding do not conform to CGMP, your PET drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, we reviewed your firm’s drug listing submissions in FDA’s electronic Drug Registration and Listing System (eDRLS) and found that you failed to update the listing for your PET human prescription drug product, Fludeoxyglucose F18 (NDC 76451-118), as required under section 510(j) of the FD&C Act (21 U.S.C. 360(j)) and 21 CFR part 207.\nThus, Fludeoxyglucose F18 is not properly listed, and your firm has not fulfilled its listing obligations under 510(j) of the FD&C Act (21 U.S.C. 360(j)) and 21 CFR 207, which is prohibited under section 301(p) of the FD&C Act (21 U.S.C. 331(p)). This violation is described in more detail below.\nWe reviewed your June 30, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your facilities are not adequate to ensure the prevention of contamination of equipment or product by substances, personnel, or environmental conditions that could reasonably be expected to have an adverse effect on product quality. Procedures to ensure that all equipment is clean, suitable for its intended purposes, properly installed, maintained, and capable of repeatedly producing valid results, are not adequately followed (21 CFR 212.30(a) and (b)).\nFacility Suitability\nYou failed to ensure that your facility is adequately designed and controlled to prevent contamination of the sterile injectable PET drugs you manufacture. For example, our investigator observed your operator making aseptic connections in an open benchtop area, without adequate aseptic environmental conditions. Furthermore, our investigator observed that Hot Cell #(b)(4), which is used to manufacture Fludeoxyglucose F-18 (FDG), was in a poor state of repair, with rust on the manipulator arms and with visible residue on surfaces near where the finished product is filtered into sterile vials.\nIn your response, you state that you made facility and equipment repairs, including removal of rust and replacement of the chipped lead shielding in your hot cell. Your response is inadequate because you do not evaluate your facility, process, and equipment for potential routes of contamination or address how you will improve your process to ensure that your product is properly protected from the environment during aseptic connections.\nAppropriate aseptic environments should be used for critical aseptic manipulation in the production and testing of PET drugs.\nEnvironmental Monitoring\nYou failed to establish and follow adequate testing procedures for environmental monitoring (EM) for your aseptic manufacturing area. For example, your Hot Cell #(b)(4), where the FDG drug product is filtered into the final product vials, is not monitored. Further, the alert and action levels that you established in your standard operating procedure (“SOP for Environmental Monitoring of Hot Cells”) for EM are not appropriate. For surface samples taken in your hot cell, your procedure does not require an investigation unless (b)(4) or more colony-forming units are recovered from a single sample. Your high action levels allow for an unacceptable risk of contamination to your product.\nIn your response, you indicate that you lack an understanding of where the environmental monitoring should occur, and that you will update your EM to include a location “adjacent to the sterile closure.” Your response is inadequate because you do not address how you will determine the appropriate sampling location and frequency for EM.\nPET drug products have short expiry periods. Thus, your PET drug products are released and administered before the results of batch specific sterility testing and EM are known. Therefore, adequate microbiological monitoring of the aseptic environment is essential during critical aseptic manipulation. A vigilant, ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\nIn response to this letter, provide:\nA comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes but is not limited to:\no All human interactions within the ISO (b)(4) area\no Equipment placement and ergonomics\no Air quality in the ISO (b)(4) area and surrounding room\no Facility layout\no Personnel flows and material flows (throughout all rooms used to conduct and support sterile operations)\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\nYour updated procedure(s) demonstrating that aseptic connections will be conducted in an appropriate environment (e.g., ISO (b)(4) aseptic workstation).\nAn independent assessment of your EM program, including but not limited to establishing appropriate limits, sampling locations and frequencies, investigating deviations, and trend analysis, and a comprehensive corrective action and preventive action plan.\nYour action levels for ISO (b)(4) surfaces, air, and operator gloves, and revised procedures that describe the appropriate response to contamination in critical environments.\n2. Your firm failed to have adequate production and process controls to ensure the consistent production of a PET drug that meets the applicable standards of identity, strength, quality, and purity (21 CFR 212.50).\nYou failed to ensure that your operators are appropriately gowned to adequately protect the sterile injectable PET drugs you manufacture. For example, our investigator observed exposed skin and hair on your operator during the manufacturing of FDG lot (b)(4). The operators’ skin on their arms was exposed while they were setting up production in an open benchtop area of the room (i.e. with inadequate aseptic environmental conditions). The operators’ skin was also exposed while leaning into Hot Cell #(b)(4) to set up for product (b)(4) into sterile vials. Additionally, another operator was observed reaching into the ISO (b)(4) laminar flow hood with exposed skin on the operator’s arms and face while performing sterility testing for FDG lots (b)(4) and (b)(4).\nFurthermore, you failed to adequately requalify two of the (b)(4) operators at least annually by conducting a media fill to assess their aseptic processing technique. For example, one of your operators had not been requalified to perform PET drug manufacturing using process simulations (media fills) since April 2021. However, the operator manufactured FDG as recently as June 2025.\nIn your response, you indicate that the two operators were removed from production and a media fill was initiated. However, your response is inadequate because you do not provide a retrospective assessment of the potential impact to drug products manufactured from 2021 to present. Your response is also inadequate because you do not comprehensively address how you will ensure that your gowning program is adequate, including whether appropriate gowning will be used.\nAdequate gowning is an essential part of environmental control because gowns provide a barrier to prevent operators from contaminating the drug product. Personnel should be adequately trained and qualified to ensure their competence to perform aseptic processing of PET drugs.\nMedia fills should simulate the aseptic production process, including but not limited to the aseptic assembly of the container\u002Fclosure system through filling of the PET drug into final containers. Operators should be requalified annually by conducting one media fill run. See FDA’s guidance document Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F81974\u002Fdownload.\nIn response to this letter, provide:\nA remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability and assures that manufacturing operations meet appropriate parameters and quality standards. This includes but is not limited to evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\nA comprehensive assessment of your gowning program, including but not limited to how you will establish adequate gowning.\nThe report and results for the media fill initiated on June 16, 2025, and any subsequent media fills conducted.\nA comprehensive assessment of your media fill procedure, including but not limited to how you will ensure that operators are requalified annually.\n3. Your firm failed to have laboratory methods suitable for their intended use and sufficiently sensitive, specific, accurate, and reproducible (21 CFR 212.60).\nYou failed to establish and follow adequate testing procedures for sterility testing of your sterile injectable PET drugs. For example, our investigator observed your operator performing sterility testing using poor aseptic technique, including opening sterile components outside of the ISO (b)(4) laminar flow hood before use. Also, our investigator observed your chemist vigorously shaking the sterility test sample tubes before reading the results. Shaking the sterility test sample tubes may mask the test results and may impact a person’s ability to visually detect turbidity, visible colonies, or other evidence of microorganisms.\nIn your response, you indicate that you updated your sterility testing procedure. However, your response is inadequate because it lacks information about how you will ensure that your procedures are sufficiently detailed for operators to follow and how you will ensure that sterility testing is adequately performed.\nTesting is a critical control that provides assurance that your PET drug products are sterile and therefore suitable for their intended use. It is important that you follow established, appropriate procedures to ensure that your sterility testing can detect the presence of microorganisms.\nIn response to this letter, provide:\nA comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA comprehensive assessment of your sterility testing program, including but not limited to material flow and environmental monitoring.\nA comprehensive review of your sterility testing procedure relative to the expectations in the United States Pharmacopeia (USP) General Chapter \u003C71,> Sterility Tests.\nYour most recent static and dynamic smoke studies performed for the laminar flow hood.\nDrug Listing Violations\nSection 510(j) of the FD&C Act (21 U.S.C. 360(j)) and 21 CFR part 207 set forth the requirements for the listing of drugs. Under 21 CFR 207.57(b), registrants are required to update drug listing information twice each year, in June and December. Under 21 CFR 207.57(b)(2), registrants may satisfy the listing update requirement with respect to unchanged listing information by making a single “no changes” certification during the October 1 through December 31 annual registration period. If the drug listing data is not updated or certified, the outdated listing data will get inactivated at the next scheduled FDA inactivation period.1 You failed to update or certify Fludeoxyglucose F18 as required.\nTherefore, Fludeoxyglucose F18 is not properly listed under section 510(j) of the FD&C Act. Failure to properly list a drug in accordance with 510(j) of the FD&C Act is prohibited under section 301(p) of the FD&C Act (21 U.S.C. 331(p)).\nComplete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply-chain security, and postmarket surveillance. Establishment registration and drug listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\nIn addition, we note that your drug listings for Ammonia N 13 (NDC 76451-013) and Sodium Fluoride F-18 (NDC 76451-018) also have not been updated or certified. Please update the listing information for these drugs to reflect their current status. If you no longer manufacture and distribute these drugs, then the drugs must be discontinued by adding an end marketing date. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding your drug listings, please contact us at eDRLS@fda.hhs.gov for further assistance.\nIt is your responsibility to ensure that all drugs manufactured at your establishment comply with all establishment registration and drug listing requirements under section 510 of the FD&C Act, 21 U.S.C. 360, 21 CFR part 207, and all other applicable FDA regulations. Registration and listing information and instructions on how to properly register an establishment or submit drug listings can be found at Electronic Drug Registration and Listing Instructions.\nGuidance on Positron Emission Tomography (PET) Drugs\nSee FDA’s guidance document, PET Drugs—Current Good Manufacturing Practice, to help you meet the CGMP requirements when manufacturing PET drugs, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71013\u002Fdownload. This guidance document also references FDA’s guidance document, Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice for additional concepts and expectations that may apply to PET drug manufacturing, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days2. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009143510 and ATTN: Lynnsey Renn.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_________________\n1 See 84 FR 40417 (https:\u002F\u002Fwww.regulations.gov\u002Fdocument\u002FFDA-2019-N-2374-0001).\n2 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","3D Imaging Drug Design and Development LLC","3d-imaging-drug-design-and-development-llc-716213-12042025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F3d-imaging-drug-design-and-development-llc-716213-12042025","2026-10-26T08:07:47.726648+00:00","2025-12-16","716213","Drugs","Marc S. Berridge, Ph.D.","2026-08-19T07:21:49.964+00:00","320-26-23","2025-12-04",{"id":55,"raw":56,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":20,"letter_url":67,"updated_at":68,"action_type":23,"case_status":24,"posted_date":69,"marcs_cms_no":70,"product_type":27,"closeout_date":20,"issuing_office":60,"recipient_name":71,"body_fetched_at":72,"delivery_method":73,"recipient_title":20,"reference_number":20,"action_taken_date":74,"medical_device_id":20,"response_letter_date":20},892,[57,58,59,60,61,13,13,13],"\u003Ctime datetime=\"2025-05-20T04:00:00Z\">05\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-22T04:00:00Z\">10\u002F22\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchongqing-tianrun-food-development-co-ltd-686323-10222024\">Chongqing Tianrun Food Development Co., Ltd\u003C\u002Fa>","Human Foods Program","Low Acid Canned Food Regulation\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Yu Liao\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Chongqing Tianrun Food Development Co., Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 99 Jiayuan Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chongqing\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sichuan Sheng\u003C\u002Fspan>,\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:531683392@qq.com\"> 531683392@qq.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 22, 2024\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Reference No. 686323\u003C\u002Fp>\u003Cp>Dear Mr. Liao:\u003C\u002Fp>\u003Cp>The United States (U.S.) Food and Drug Administration (FDA) inspected your low-acid canned food (LACF) product facility, located at No. 99 Jiayuan Ave Chongqing, Sichaun Province, China from April 17 to April 19, 2024. During the inspection, we found that your firm had serious deviations from the Emergency Permit Control regulation, Title 21, Code of Federal Regulations, Part 108 (21 CFR 108)) and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers regulation Part 113 (21 CFR 113). At the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations that lists the serious deviations found at your firm.\u003C\u002Fp>\u003Cp>As a manufacturer of LACF products intended for export to the United States, you are required to comply with the Federal Food Drug and Cosmetic Act (the Act) and the Federal regulations relating to the processing of low-acid foods packaged in hermetically sealed containers. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. § 344. A temporary emergency permit may be required for thermally processed low-acid foods packaged in hermetically sealed containers whenever a processor has failed to fulfill the requirements of 21 CFR 108.35, including registration, and filing of process information, and the mandatory requirements in 21 CFR Parts 113. Regulations specific to the processing of LACF products are described in 21 CFR 108 and 21 CFR 113. As outlined in these regulations, a commercial processor that does not adhere to all the mandatory requirements of 21 CFR 108.35 and 21 CFR 113 could be subjected to an immediate application of the emergency permit control provisions of section 404 of the Act (21 U.S.C. 344). As stated in 21 CFR 108.35(k), for imported products, in lieu of issuing an order of determination that a permit is required before products from a commercial processor can be introduced into interstate commerce, FDA may take steps to refuse admission of the commercial processor's products under section 801 of the Act (21 U.S.C. 381) when offered for entry into the United States. Violation of the mandatory requirements set forth in 21 CFR 108.35 and 21 CFR 113 renders your 230g pouches of roasted gluten adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4). You can find the Act and LACF regulations through links in FDA’s home page at www.fda.gov.\u003C\u002Fp>\u003Cp>FDA received your written response, describing corrective actions taken and planned by your firm, on April 30, 2024. After reviewing the inspectional findings and responses that your firm provided, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility. We address your response below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Emergency Permit Control regulation, (21 CFR 108) and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers (21 CFR 113)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>1. A commercial processor of thermally processed low-acid foods in hermetically sealed containers must register as a food canning establishment and file a form FDA 2541 (food canning establishment registration) with the FDA within 10 days after first engaging in the manufacture, processing, or packing, as required by 21 CFR 108.35(c)(1).\u003C\u002Fp>\u003Cp>However, you did not register as a food canning establishment (FCE) before shipping your low-acid\u002F canned tofu products to the U.S., including seasoned tofu snack vacuum packaged \u003Cstrong>(b)(4)\u003C\u002Fstrong> inner bag. Your response stated you would work with a third-party to register your facility as an FCE. You submitted your FCE registration on May 30, 2024. However, based upon our records you exported low-acid canned tofu products to the United States multiple times between July 2023 and April 2024 before registering as an FCE.\u003C\u002Fp>\u003Cp>2. A commercial processor engaged in the processing of acidified foods must file information regarding their scheduled processes with the FDA prior to the packing of a new product not later than 60 days after registration, as required by 21 CFR 108.35(c)(2). However, at the time of our inspection, you had not filed any scheduled processes for low-acid canned tofu products you ship to the U.S., including lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong> TRAD of QQ Dried Beans utilizing a \u003Cstrong>(b)(4)\u003C\u002Fstrong> packaging size.\u003C\u002Fp>\u003Cp>On June 12, 2024, you filed scheduled processes for QQ Dried Bean Curd (Spicy Flavor) \u003Cstrong>(b)(4)\u003C\u002Fstrong> (SID \u003Cstrong>(b)(4)\u003C\u002Fstrong>), Chongqing Style Dried Tofu \u003Cstrong>(b)(4) \u003C\u002Fstrong>(SID \u003Cstrong>(b)(4)\u003C\u002Fstrong>), Dried tofu with Mushroom \u003Cstrong>(b)(4)\u003C\u002Fstrong> (SID \u003Cstrong>(b)(4)\u003C\u002Fstrong>), and on July 22, 2024, you filed a scheduled process for Fried Tofu with Sauce \u003Cstrong>(b)(4)\u003C\u002Fstrong> (SID \u003Cstrong>(b)(4)\u003C\u002Fstrong>). A review of your filed scheduled processes found that you only uploaded heat distribution studies in “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Furthermore, the container sizes listed in your filed scheduled processes do not appear to match the container packaging sizes of your LACF tofu products shipped to the U.S. reviewed during your inspection. In your response to this Warning Letter, you should describe which products are covered by your filed scheduled processes, including fill weight and container size. Furthermore, if you are processing products for the U.S. market in other retorts you should provide evidence that the filed critical parameters in each of your scheduled processes can be achieved when processed in any of your retorts.\u003C\u002Fp>\u003Cp>3. Your firm did not provide evidence that the scheduled processes for the low-acid food products that you manufacture were established by a qualified person who has expert knowledge acquired through appropriate training and experience in thermal processing requirements for low-acid foods in hermetically sealed containers, as required by 21 CFR 113.83.\u003C\u002Fp>\u003Cp>Specifically, you have \u003Cstrong>(b)(4)\u003C\u002Fstrong> still water immersion retorts which you use interchangeably for all low-acid canned tofu products shipped to the U.S.; identified as retorts \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During our inspection, our investigator reviewed all your available data from your process authority for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> retorts and found that either you did not have any heat distribution data for a given retort or the process identified by the heat distribution data available was established for different container sizes and retort configurations. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Retorts \u003Cstrong>(b)(4)\u003C\u002Fstrong> were installed in 2017, however, no heat distribution studies have been performed for retorts \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Your process authority reported in your heat distribution studies for \u003Cstrong>(b)(4)\u003C\u002Fstrong> that higher temperatures are required during processing of \u003Cstrong>(b)(4) \u003C\u002Fstrong>packaging types, however, you have not implemented any process corrections to reflect this data and have made no adjustments to temperatures during routine processing of this package size.\u003C\u002Fli>\u003Cli>No heat distribution testing for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> packaging type has been conducted for retorts \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On April 8, 2024, you shipped QQ Dried Beans \u003Cstrong>(b)(4)\u003C\u002Fstrong> packaging size lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> TRAD to your trading company for export to the United processed in retorts \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>The heat distribution study for retorts \u003Cstrong>(b)(4)\u003C\u002Fstrong> were tested with a maximum of 5 kg of product per tray. However, you fill \u003Cstrong>(b)(4)\u003C\u002Fstrong> kg of product per tray for all retorts for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> flexible packages. Your Production and Quality Managers stated your heat distribution study for retorts \u003Cstrong>(b)(4)\u003C\u002Fstrong> was performed for a different package type, which only fills 5 kg per tray.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your translated response dated April 30, 2024, you committed to contacting a process authority to conduct thermal distribution studies on all retorts and heat penetration studies for all product packaging sizes and configurations. You also committed to registering as a FCE and filing scheduled processes established by your process authority with the FDA after completion. You did not provide any supporting documentation in your response to the FDA’s inspectional observations demonstrating that you had your process authority evaluate each product type, container size, and packaging configuration in all retorts being used to manufacture product to be shipped to the U.S. In your response to this letter, you should provide information identifying all products, fill weights, and container sizes shipped to the U.S. with corresponding filed scheduled process number (SID identifier); provide information documenting which retorts are being used for processing; and provide supporting documentation that each of your filed scheduled processes has been established by a competent process authority supported by temperature distribution and heat penetration studies in each applicable retort, as required by 21 CFR 113.83.\u003C\u002Fp>\u003Cp>4. You did not measure and record critical factors specified in the scheduled process at intervals of sufficient frequency to ensure that the factors were within the limits specified in the scheduled process, as required by 21 CFR 113.40(b)(15).\u003C\u002Fp>\u003Cp>Your firm processes LACF tofu products for the U.S. market in a horizontal water in still retorts. You have scheduled processes established by your process authority for the processing in these retorts, but you do not measure, nor maintain records of, the critical factors for the water immersion retort process including initial temperature (IT), fill weight, package thickness, processing temperature, processing time and processing pressure as critical for delivery of the scheduled process. Your retorts are not equipped with continuous temperature recording devices and no operator checks are made during the process. Furthermore, routine operator checks are not made during the process for processing pressure. All time, temperature and pressure entries are recorded to indicate the set point of the equipment program that is run, and do not reflect actual values checked by the operator.\u003C\u002Fp>\u003Cp>Since you do not measure and record your critical parameters, you are unable to identify when your process deviates from the scheduled process, as required by 21 CFR 113.89. Our investigator reviewed your consumer complaints from 2023 until 2024 found at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> consumer complaints indicating more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> individual lots manufactured by your firm for various vacuum packaged products where customers have reported swollen vacuum packaged bags to your firm. There has been no contact with your process authority or review of your firm’s processing or handling procedures to investigate these lots or to determine the reason for the apparent under processing, which is also required by 21 CFR 113.89.\u003C\u002Fp>\u003Cp>In your translated response dated April 30, 2024, you committed to purchasing an electronic temperature recorder to monitor the sterilization temperature every minute; add a process for monitoring the center temperature of the product before sterilization; strictly implement the critical parameters associated with each product; and maintain records. However, you did not provide any implementation records for your promised corrective actions to demonstrate that you are monitoring your critical process parameters established in your filed scheduled processes. Furthermore, you must also ensure that that when your critical parameters are not met that you evaluate these process deviations, as required by 21 CFR 113.89.\u003C\u002Fp>\u003Cp>5. You must have a means to determine the water level in the retort during operation, e.g., by using a sensor, gage, water glass, or petcock(s) and record the water level at intervals sufficient to ensure its adequacy, as required by 21 CFR 113.40(b)(10). However, you do not check or record the water level during processing. Specifically, on April 18, 2024, our investigator observed a full retort cycle, and your operator did not observe or record the water level to ensure product was covered with water for the duration of the come-up time and sterilization cycle. Furthermore, during our investigator’s review of your horizontal water in still retort, he observed significant residue buildup in the water return lines on retort \u003Cstrong>(b)(4)\u003C\u002Fstrong> and an unknown object lodged in the water line on retort \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your operators were unsure exactly how the retorts functioned and the potential impact of the observed conditions on operation of retort \u003Cstrong>(b)(4) \u003C\u002Fstrong>and retort \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In your translated response dated April 30, 2024, you committed to add water inspection and sterilization inspection records, clean the water pipe wall regularly, and formulate a system for strict implementation. However, you did not provide any implementation records for the monitoring of the water level during retort operations. You also did not provide any supporting documentation to demonstrate you cleaned the water lines of retort \u003Cstrong>(b)(4)\u003C\u002Fstrong> and implement inspection of the water lines for all \u003Cstrong>(b)(4)\u003C\u002Fstrong> retorts.\u003C\u002Fp>\u003Cp>6. You must have conduct appropriate detailed inspections and tests at intervals of sufficient frequency to ensure proper closing machine performance and consistently reliable hermetic seal production and maintain records of the tests, as required by 21 CFR 113.60(a)(3). However, you do not maintain records of the examination of the pouch container closures for your LACF tofu products shipped to the U.S. Specifically, you only perform hermetic seal adequacy checks at startup and do not record any hermetic seal checks at the packaging step. Our investigator reviewed your consumer complaints and observed multiple complaints of leaking bags and microbial contamination due to poor seals.\u003C\u002Fp>\u003Cp>In your translated response dated April 30, 2024, you committed to modify your process to require that the packaging sealing of the product be tested every hour and record it. However, you did not provide any implementation records for this corrective action.\u003C\u002Fp>\u003Cp>7. You must have plant personnel involved in thermal processing systems or other critical factors of the operation under the operating supervision of a person who has attended a school approved by FDA to comply with 21 CFR 113.10. Specifically, our inspection revealed no one at your firm has received training in critical factors in the production of LACF products nor aseptic processing.\u003C\u002Fp>\u003Cp>In your translated response dated April 30, 2024, you committed to regularly conduct professional knowledge training for sterilization operators and keep records. You did not provide records demonstrating this training had been scheduled or completed. You did not provide any information regarding the qualifications of the trainer or that the training corresponds to a course of instruction approved by the Commissioner of the U.S. Food and Drug Administration to meet the requirements of 21 21 CFR 108.35(g),\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. Responding in English will help to assist us in our review of your documentation.\u003C\u002Fp>\u003Cp>If you do not respond to this letter or if we find your response inadequate, we may take further action. For instance, we may take action to refuse admission of your imported acidified food products under section 801(a) of the Act (21 U.S.C. 381(a)) including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, examples of Import Alerts that convey information specific to foreign firms that are not in compliance with the acidified food regulations (21 CFR 108 and 114) are Import Alert 99-37, Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods without Filed Scheduled Processes and Import Alert #99-38, Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods due to Inadequate Process Control. These alerts can be found on FDA’s web site at: www.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\u003Cp>This letter may not list all the deviations at your facility. You are responsible for ensuring that all processing plants you operate are in compliance with the Act and all applicable FDA regulations, including the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations. You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\u003C\u002Fp>\u003Cp>Please send your reply via email to Victoria.Wagoner@fda.hhs.gov or to the Food and Drug Administration, Attention: Victoria Wagoner, Compliance Officer, Office of Compliance and Enforcement, Office of Enforcement, Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. Please reference 686323 on any submissions and within the subject line of any emails to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, J.D.\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nYu Liao\n\nRecipient Title\n\nGeneral Manager\n\nChongqing Tianrun Food Development Co., Ltd\n\nNo. 99 Jiayuan Ave\n\nChongqing\n\nSichuan Sheng,\n\nChina\n\n531683392@qq.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nOctober 22, 2024\nWARNING LETTER\nReference No. 686323\nDear Mr. Liao:\nThe United States (U.S.) Food and Drug Administration (FDA) inspected your low-acid canned food (LACF) product facility, located at No. 99 Jiayuan Ave Chongqing, Sichaun Province, China from April 17 to April 19, 2024. During the inspection, we found that your firm had serious deviations from the Emergency Permit Control regulation, Title 21, Code of Federal Regulations, Part 108 (21 CFR 108)) and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers regulation Part 113 (21 CFR 113). At the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations that lists the serious deviations found at your firm.\nAs a manufacturer of LACF products intended for export to the United States, you are required to comply with the Federal Food Drug and Cosmetic Act (the Act) and the Federal regulations relating to the processing of low-acid foods packaged in hermetically sealed containers. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. § 344. A temporary emergency permit may be required for thermally processed low-acid foods packaged in hermetically sealed containers whenever a processor has failed to fulfill the requirements of 21 CFR 108.35, including registration, and filing of process information, and the mandatory requirements in 21 CFR Parts 113. Regulations specific to the processing of LACF products are described in 21 CFR 108 and 21 CFR 113. As outlined in these regulations, a commercial processor that does not adhere to all the mandatory requirements of 21 CFR 108.35 and 21 CFR 113 could be subjected to an immediate application of the emergency permit control provisions of section 404 of the Act (21 U.S.C. 344). As stated in 21 CFR 108.35(k), for imported products, in lieu of issuing an order of determination that a permit is required before products from a commercial processor can be introduced into interstate commerce, FDA may take steps to refuse admission of the commercial processor's products under section 801 of the Act (21 U.S.C. 381) when offered for entry into the United States. Violation of the mandatory requirements set forth in 21 CFR 108.35 and 21 CFR 113 renders your 230g pouches of roasted gluten adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4). You can find the Act and LACF regulations through links in FDA’s home page at www.fda.gov.\nFDA received your written response, describing corrective actions taken and planned by your firm, on April 30, 2024. After reviewing the inspectional findings and responses that your firm provided, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility. We address your response below.\nEmergency Permit Control regulation, (21 CFR 108) and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers (21 CFR 113)\n1. A commercial processor of thermally processed low-acid foods in hermetically sealed containers must register as a food canning establishment and file a form FDA 2541 (food canning establishment registration) with the FDA within 10 days after first engaging in the manufacture, processing, or packing, as required by 21 CFR 108.35(c)(1).\nHowever, you did not register as a food canning establishment (FCE) before shipping your low-acid\u002F canned tofu products to the U.S., including seasoned tofu snack vacuum packaged (b)(4) inner bag. Your response stated you would work with a third-party to register your facility as an FCE. You submitted your FCE registration on May 30, 2024. However, based upon our records you exported low-acid canned tofu products to the United States multiple times between July 2023 and April 2024 before registering as an FCE.\n2. A commercial processor engaged in the processing of acidified foods must file information regarding their scheduled processes with the FDA prior to the packing of a new product not later than 60 days after registration, as required by 21 CFR 108.35(c)(2). However, at the time of our inspection, you had not filed any scheduled processes for low-acid canned tofu products you ship to the U.S., including lot #(b)(4) TRAD of QQ Dried Beans utilizing a (b)(4) packaging size.\nOn June 12, 2024, you filed scheduled processes for QQ Dried Bean Curd (Spicy Flavor) (b)(4) (SID (b)(4)), Chongqing Style Dried Tofu (b)(4) (SID (b)(4)), Dried tofu with Mushroom (b)(4) (SID (b)(4)), and on July 22, 2024, you filed a scheduled process for Fried Tofu with Sauce (b)(4) (SID (b)(4)). A review of your filed scheduled processes found that you only uploaded heat distribution studies in “(b)(4)” and “(b)(4).” Furthermore, the container sizes listed in your filed scheduled processes do not appear to match the container packaging sizes of your LACF tofu products shipped to the U.S. reviewed during your inspection. In your response to this Warning Letter, you should describe which products are covered by your filed scheduled processes, including fill weight and container size. Furthermore, if you are processing products for the U.S. market in other retorts you should provide evidence that the filed critical parameters in each of your scheduled processes can be achieved when processed in any of your retorts.\n3. Your firm did not provide evidence that the scheduled processes for the low-acid food products that you manufacture were established by a qualified person who has expert knowledge acquired through appropriate training and experience in thermal processing requirements for low-acid foods in hermetically sealed containers, as required by 21 CFR 113.83.\nSpecifically, you have (b)(4) still water immersion retorts which you use interchangeably for all low-acid canned tofu products shipped to the U.S.; identified as retorts (b)(4). During our inspection, our investigator reviewed all your available data from your process authority for your (b)(4) retorts and found that either you did not have any heat distribution data for a given retort or the process identified by the heat distribution data available was established for different container sizes and retort configurations. For example:\nRetorts (b)(4) were installed in 2017, however, no heat distribution studies have been performed for retorts (b)(4).\nYour process authority reported in your heat distribution studies for (b)(4) that higher temperatures are required during processing of (b)(4) packaging types, however, you have not implemented any process corrections to reflect this data and have made no adjustments to temperatures during routine processing of this package size.\nNo heat distribution testing for the (b)(4) packaging type has been conducted for retorts (b)(4). On April 8, 2024, you shipped QQ Dried Beans (b)(4) packaging size lot # (b)(4) TRAD to your trading company for export to the United processed in retorts (b)(4).\nThe heat distribution study for retorts (b)(4) were tested with a maximum of 5 kg of product per tray. However, you fill (b)(4) kg of product per tray for all retorts for the (b)(4) flexible packages. Your Production and Quality Managers stated your heat distribution study for retorts (b)(4) was performed for a different package type, which only fills 5 kg per tray.\nIn your translated response dated April 30, 2024, you committed to contacting a process authority to conduct thermal distribution studies on all retorts and heat penetration studies for all product packaging sizes and configurations. You also committed to registering as a FCE and filing scheduled processes established by your process authority with the FDA after completion. You did not provide any supporting documentation in your response to the FDA’s inspectional observations demonstrating that you had your process authority evaluate each product type, container size, and packaging configuration in all retorts being used to manufacture product to be shipped to the U.S. In your response to this letter, you should provide information identifying all products, fill weights, and container sizes shipped to the U.S. with corresponding filed scheduled process number (SID identifier); provide information documenting which retorts are being used for processing; and provide supporting documentation that each of your filed scheduled processes has been established by a competent process authority supported by temperature distribution and heat penetration studies in each applicable retort, as required by 21 CFR 113.83.\n4. You did not measure and record critical factors specified in the scheduled process at intervals of sufficient frequency to ensure that the factors were within the limits specified in the scheduled process, as required by 21 CFR 113.40(b)(15).\nYour firm processes LACF tofu products for the U.S. market in a horizontal water in still retorts. You have scheduled processes established by your process authority for the processing in these retorts, but you do not measure, nor maintain records of, the critical factors for the water immersion retort process including initial temperature (IT), fill weight, package thickness, processing temperature, processing time and processing pressure as critical for delivery of the scheduled process. Your retorts are not equipped with continuous temperature recording devices and no operator checks are made during the process. Furthermore, routine operator checks are not made during the process for processing pressure. All time, temperature and pressure entries are recorded to indicate the set point of the equipment program that is run, and do not reflect actual values checked by the operator.\nSince you do not measure and record your critical parameters, you are unable to identify when your process deviates from the scheduled process, as required by 21 CFR 113.89. Our investigator reviewed your consumer complaints from 2023 until 2024 found at least (b)(4) consumer complaints indicating more than (b)(4) individual lots manufactured by your firm for various vacuum packaged products where customers have reported swollen vacuum packaged bags to your firm. There has been no contact with your process authority or review of your firm’s processing or handling procedures to investigate these lots or to determine the reason for the apparent under processing, which is also required by 21 CFR 113.89.\nIn your translated response dated April 30, 2024, you committed to purchasing an electronic temperature recorder to monitor the sterilization temperature every minute; add a process for monitoring the center temperature of the product before sterilization; strictly implement the critical parameters associated with each product; and maintain records. However, you did not provide any implementation records for your promised corrective actions to demonstrate that you are monitoring your critical process parameters established in your filed scheduled processes. Furthermore, you must also ensure that that when your critical parameters are not met that you evaluate these process deviations, as required by 21 CFR 113.89.\n5. You must have a means to determine the water level in the retort during operation, e.g., by using a sensor, gage, water glass, or petcock(s) and record the water level at intervals sufficient to ensure its adequacy, as required by 21 CFR 113.40(b)(10). However, you do not check or record the water level during processing. Specifically, on April 18, 2024, our investigator observed a full retort cycle, and your operator did not observe or record the water level to ensure product was covered with water for the duration of the come-up time and sterilization cycle. Furthermore, during our investigator’s review of your horizontal water in still retort, he observed significant residue buildup in the water return lines on retort (b)(4) and an unknown object lodged in the water line on retort (b)(4). Your operators were unsure exactly how the retorts functioned and the potential impact of the observed conditions on operation of retort (b)(4) and retort (b)(4).\nIn your translated response dated April 30, 2024, you committed to add water inspection and sterilization inspection records, clean the water pipe wall regularly, and formulate a system for strict implementation. However, you did not provide any implementation records for the monitoring of the water level during retort operations. You also did not provide any supporting documentation to demonstrate you cleaned the water lines of retort (b)(4) and implement inspection of the water lines for all (b)(4) retorts.\n6. You must have conduct appropriate detailed inspections and tests at intervals of sufficient frequency to ensure proper closing machine performance and consistently reliable hermetic seal production and maintain records of the tests, as required by 21 CFR 113.60(a)(3). However, you do not maintain records of the examination of the pouch container closures for your LACF tofu products shipped to the U.S. Specifically, you only perform hermetic seal adequacy checks at startup and do not record any hermetic seal checks at the packaging step. Our investigator reviewed your consumer complaints and observed multiple complaints of leaking bags and microbial contamination due to poor seals.\nIn your translated response dated April 30, 2024, you committed to modify your process to require that the packaging sealing of the product be tested every hour and record it. However, you did not provide any implementation records for this corrective action.\n7. You must have plant personnel involved in thermal processing systems or other critical factors of the operation under the operating supervision of a person who has attended a school approved by FDA to comply with 21 CFR 113.10. Specifically, our inspection revealed no one at your firm has received training in critical factors in the production of LACF products nor aseptic processing.\nIn your translated response dated April 30, 2024, you committed to regularly conduct professional knowledge training for sterilization operators and keep records. You did not provide records demonstrating this training had been scheduled or completed. You did not provide any information regarding the qualifications of the trainer or that the training corresponds to a course of instruction approved by the Commissioner of the U.S. Food and Drug Administration to meet the requirements of 21 21 CFR 108.35(g),\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. Responding in English will help to assist us in our review of your documentation.\nIf you do not respond to this letter or if we find your response inadequate, we may take further action. For instance, we may take action to refuse admission of your imported acidified food products under section 801(a) of the Act (21 U.S.C. 381(a)) including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, examples of Import Alerts that convey information specific to foreign firms that are not in compliance with the acidified food regulations (21 CFR 108 and 114) are Import Alert 99-37, Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods without Filed Scheduled Processes and Import Alert #99-38, Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods due to Inadequate Process Control. These alerts can be found on FDA’s web site at: www.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\nThis letter may not list all the deviations at your facility. You are responsible for ensuring that all processing plants you operate are in compliance with the Act and all applicable FDA regulations, including the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations. You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\nPlease send your reply via email to Victoria.Wagoner@fda.hhs.gov or to the Food and Drug Administration, Attention: Victoria Wagoner, Compliance Officer, Office of Compliance and Enforcement, Office of Enforcement, Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. Please reference 686323 on any submissions and within the subject line of any emails to us.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, J.D.\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Chongqing Tianrun Food Development Co., Ltd","chongqing-tianrun-food-development-co-ltd-686323-10222024","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchongqing-tianrun-food-development-co-ltd-686323-10222024","2026-10-26T08:08:14.937582+00:00","2025-05-20","686323","Yu Liao","2026-08-19T16:45:29.331+00:00","Via Express Delivery","2024-10-22",{"id":76,"raw":77,"subject":82,"body_html":83,"body_text":84,"firm_name":85,"letter_id":86,"created_at":87,"fei_number":20,"letter_url":88,"updated_at":89,"action_type":23,"case_status":24,"posted_date":90,"marcs_cms_no":91,"product_type":92,"closeout_date":20,"issuing_office":81,"recipient_name":93,"body_fetched_at":94,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":95,"medical_device_id":20,"response_letter_date":20},3206,[78,79,80,81,82,13,13,13],"\u003Ctime datetime=\"2021-08-17T13:20:00Z\">08\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-17T04:00:00Z\">06\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftianjin-bolang-science-technology-development-co-ltd-614851-06172021\">Tianjin Bolang Science-Technology Development Co., Ltd.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Lin Qi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tianjin Bolang Science-Technology Development Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>D-401, Hi-Tech Green Industrial Base\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Huayuan Industrial Area\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tianjin Shi\u003C\u002Fspan>, \u003Cspan>300384\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nJune 17, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Qi:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Tianjin, China on March 22, 2021, through March 30, 2021, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Otoscopes, Rigid Laryngoscopes, and Rigid Nasopharyngoscopes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cstrong>Code of Federal Regulations\u003C\u002Fstrong> (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received a response from Mr. Zhang Li, Management Representative, dated April 19, 2021, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address your response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). For example, your firm has not established Design Control procedures for your firm’s private label manufactured endoscopic medical devices for the U.S. market, including the Class II Rigid Nasopharyngoscope. In addition, your firm did not conduct Design and Development activities for the Rigid Nasopharyngoscope. The activities not conducted include: Design Input, Design Output, Design Review, Design Verification, Design Validation, Design Transfer, Design Changes, and Design History File.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm identified its plan to establish a Design Control procedure according to 21 CFR 820.30, as well as establish a Design History File for products intended for distribution in the U.S. However, until your firm establishes Design Control procedures and a Design History File and provides a copy to the Agency for review, the adequacy of the response cannot be determined.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example, your firm has not established procedures for corrective and preventive action (CAPAs) and did not conduct any CAPAs. Your firm has also not established a system for the identification and input of quality data which may require corrective and\u002For preventive action.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm described its plan to revise the Improved Control procedures to meet requirements of 21 CFR 820.100. Also, your firm identified a planned retrospective review of quality data for the previous two years, performing corrective and preventive measures as needed. The response is not adequate because your firm did not provide details such as processes, work operations, quality records and other quality data to be analyzed. Since the investigator was not able to review and inspect production and process controls, procedures and records, FDA has no assurance quality data exists in order to perform a retrospective review. Additionally, the response does not describe how the CAPA procedure will be maintained and implemented.\u003C\u002Fp>\n\n\u003Cp>3. Failure to maintain complaint files and to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example, your firm has not established customer complaint handling procedures to ensure it is receiving complaints from its sole U.S. distributor, Ecleris. This U.S. distributor is marketing your firm’s manufactured, private label, Rigid Nasopharyngoscope. Also, your firm does not have a written agreement with its U.S. distributor requiring all complaints be provided for review and evaluation.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm indicated plans to update Measurement and Analysis of Customer Information Feedback Control procedures as required by 21 CFR 820.198 and to evaluate MDR reportable events as required by 21 CFR 803. However, during the inspection, complaint procedure and complaint records were not available for review. Therefore, a review of the procedures needs to be conducted in order to ensure it meets the requirements of 21 CFR 820.198 and details on how complaints will be retrospectively collected from customers, needs to be provided.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures for control and distribution of finished devices to ensure that only those devices approved for release are distributed and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution, as required by 21 CFR 820.160. For example, your firm has not established procedures for the control and distribution of its private label manufactured endoscopic medical devices for the U.S. market including the Rigid Nasopharyngoscope to ensure only those devices approved for release are distributed.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm states that its customer related Process Control procedures will be revised to meet the requirements of 21 CFR 820.160. According to your firm, these revised procedures will include distribution requirements for product intended for the U.S. The response is not adequate because your firm has not identified a plan to establish and maintain procedures for the control and distribution of finished devices intended for the U.S.\u003C\u002Fp>\n\n\u003Cp>5. Failure to maintain device master records (DMR's) and to ensure that each DMR is prepared and approved in accordance with 21 CFR 820.40, as required by 21 CFR 820.181. For example, your firm has not maintained Device Master Records (DMR’s) for its private label manufactured endoscopic medical devices intended for the U.S. market, including the Rigid Nasopharyngoscope.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm stated that DMR Control procedures will be established in accordance with 21 CFR 820.181. The adequacy of the response cannot be determined until your firm establishes and maintains DMR Control procedures as required by 21 CFR 820.181, and provides a copy of the procedure to the Agency for review.\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish and maintain procedures to ensure that device history records (DHR’s) for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record (DMR) and the requirements of this part, as required by 21 CFR 820.184. For example, your firm has not established DHR procedures to ensure DHRs are maintained for each device batch, lot, or unit. Your firm also has not demonstrated DHRs are maintained for manufactured devices in accordance with specifications, including its private label Rigid Nasopharyngoscope.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm states that DHR control procedures will be established to meet the requirements of 21 CFR 820.184. Until your firm establishes and maintains a DHR to demonstrate its device is manufactured in accordance with the device DMR as required by 21 CFR 820.184, and provides a copy of the procedures to the Agency for review, the adequacy of the response cannot be determined.\u003C\u002Fp>\n\n\u003Cp>7. Failure to maintain a quality system record (QSR) which includes, or refers to the location of, procedures and the documentation of activities required by this part that are not specific to a particular type of device(s), including, but not limited to, the records required by 21 CFR 820.20, as required by 21 CFR 820.186. For example, your firm ’s Quality System does not include, or refer to the location of procedures and the documentation of activities required by the Quality System regulation. During the inspection, certain procedures and documentation of the organizational structure were not available for review.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm indicated its Quality System will be revised to include: 21 CFR 820; 21 CFR 803; 21 CFR 806; and 21 CFR 807. Revision of the Quality Manual and related procedures will also occur according to your firm. Until your firm establishes and maintains a Quality System and Quality Manual procedures as required by 21 CFR 820.186, and provides a copy of the procedures to the Agency for review, the adequacy of the response cannot be determined.\u003C\u002Fp>\n\n\u003Cp>8. Failure to have sufficient personnel with the necessary education, background, training, and experience to assure that all activities required by this part are correctly performed, as required by 21 CFR 820.25(a). For example, your firm has not demonstrated it had any prior knowledge of U.S. FDA regulations and requirements including 21 CFR Part 820 - Quality System regulation.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm described the completion of employee training for 21 CFR 820; 21 CFR 803, 21 CFR 807, 21 CFR 806 and 21 CFR 830. Until your firm can demonstrate adequate employee training for all personnel, related to its Quality System as required by 21 CFR 820.25, and provides a copy of the training for Agency review, the adequacy of the response cannot be determined.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s Class II Rigid Nasopharyngoscope devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm states MDR Control procedures will be established, and a complaint retrospective review will be conducted for MDR reportable events. However, the response does not include how the electronic submission of MDR reportable events to the Agency will occur. Until your firm develops, maintains, and implements written MDR procedures as required by 21 CFR 803.17, and provides a copy of the procedures for Agency review, the response is not adequate.\u003C\u002Fp>\n\n\u003Cp>Given the serious nature of the violations of the Act, Otoscopes, Rigid Laryngoscopes, and Rigid Nasopharyngoscopes manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violations described in this letter. We will notify you regarding the adequacy of your firm’s responses and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review.\u003C\u002Fp>\n\n\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #614851 when replying. If you have any questions about the contents of this letter, please contact Shu-Chen Peng, Ph.D. at (301) 796-6481.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>for Malvina Eydelman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOHT 1: Office of Ophthalmic, Anesthesia,\u003Cbr>\nRespiratory, ENT and Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Lin Qi\n\nRecipient Title\n\nGeneral Manager\n\nTianjin Bolang Science-Technology Development Co., Ltd.\n\nD-401, Hi-Tech Green Industrial Base\n\nHuayuan Industrial Area\n\nTianjin Shi, 300384\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nJune 17, 2021\n\nDear Mr. Qi:\n\nDuring an inspection of your firm located in Tianjin, China on March 22, 2021, through March 30, 2021, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Otoscopes, Rigid Laryngoscopes, and Rigid Nasopharyngoscopes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received a response from Mr. Zhang Li, Management Representative, dated April 19, 2021, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address your response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). For example, your firm has not established Design Control procedures for your firm’s private label manufactured endoscopic medical devices for the U.S. market, including the Class II Rigid Nasopharyngoscope. In addition, your firm did not conduct Design and Development activities for the Rigid Nasopharyngoscope. The activities not conducted include: Design Input, Design Output, Design Review, Design Verification, Design Validation, Design Transfer, Design Changes, and Design History File.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your firm identified its plan to establish a Design Control procedure according to 21 CFR 820.30, as well as establish a Design History File for products intended for distribution in the U.S. However, until your firm establishes Design Control procedures and a Design History File and provides a copy to the Agency for review, the adequacy of the response cannot be determined.\n\n2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example, your firm has not established procedures for corrective and preventive action (CAPAs) and did not conduct any CAPAs. Your firm has also not established a system for the identification and input of quality data which may require corrective and\u002For preventive action.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm described its plan to revise the Improved Control procedures to meet requirements of 21 CFR 820.100. Also, your firm identified a planned retrospective review of quality data for the previous two years, performing corrective and preventive measures as needed. The response is not adequate because your firm did not provide details such as processes, work operations, quality records and other quality data to be analyzed. Since the investigator was not able to review and inspect production and process controls, procedures and records, FDA has no assurance quality data exists in order to perform a retrospective review. Additionally, the response does not describe how the CAPA procedure will be maintained and implemented.\n\n3. Failure to maintain complaint files and to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example, your firm has not established customer complaint handling procedures to ensure it is receiving complaints from its sole U.S. distributor, Ecleris. This U.S. distributor is marketing your firm’s manufactured, private label, Rigid Nasopharyngoscope. Also, your firm does not have a written agreement with its U.S. distributor requiring all complaints be provided for review and evaluation.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm indicated plans to update Measurement and Analysis of Customer Information Feedback Control procedures as required by 21 CFR 820.198 and to evaluate MDR reportable events as required by 21 CFR 803. However, during the inspection, complaint procedure and complaint records were not available for review. Therefore, a review of the procedures needs to be conducted in order to ensure it meets the requirements of 21 CFR 820.198 and details on how complaints will be retrospectively collected from customers, needs to be provided.\n\n4. Failure to establish and maintain procedures for control and distribution of finished devices to ensure that only those devices approved for release are distributed and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution, as required by 21 CFR 820.160. For example, your firm has not established procedures for the control and distribution of its private label manufactured endoscopic medical devices for the U.S. market including the Rigid Nasopharyngoscope to ensure only those devices approved for release are distributed.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm states that its customer related Process Control procedures will be revised to meet the requirements of 21 CFR 820.160. According to your firm, these revised procedures will include distribution requirements for product intended for the U.S. The response is not adequate because your firm has not identified a plan to establish and maintain procedures for the control and distribution of finished devices intended for the U.S.\n\n5. Failure to maintain device master records (DMR's) and to ensure that each DMR is prepared and approved in accordance with 21 CFR 820.40, as required by 21 CFR 820.181. For example, your firm has not maintained Device Master Records (DMR’s) for its private label manufactured endoscopic medical devices intended for the U.S. market, including the Rigid Nasopharyngoscope.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your firm stated that DMR Control procedures will be established in accordance with 21 CFR 820.181. The adequacy of the response cannot be determined until your firm establishes and maintains DMR Control procedures as required by 21 CFR 820.181, and provides a copy of the procedure to the Agency for review.\n\n6. Failure to establish and maintain procedures to ensure that device history records (DHR’s) for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record (DMR) and the requirements of this part, as required by 21 CFR 820.184. For example, your firm has not established DHR procedures to ensure DHRs are maintained for each device batch, lot, or unit. Your firm also has not demonstrated DHRs are maintained for manufactured devices in accordance with specifications, including its private label Rigid Nasopharyngoscope.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your firm states that DHR control procedures will be established to meet the requirements of 21 CFR 820.184. Until your firm establishes and maintains a DHR to demonstrate its device is manufactured in accordance with the device DMR as required by 21 CFR 820.184, and provides a copy of the procedures to the Agency for review, the adequacy of the response cannot be determined.\n\n7. Failure to maintain a quality system record (QSR) which includes, or refers to the location of, procedures and the documentation of activities required by this part that are not specific to a particular type of device(s), including, but not limited to, the records required by 21 CFR 820.20, as required by 21 CFR 820.186. For example, your firm ’s Quality System does not include, or refer to the location of procedures and the documentation of activities required by the Quality System regulation. During the inspection, certain procedures and documentation of the organizational structure were not available for review.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your firm indicated its Quality System will be revised to include: 21 CFR 820; 21 CFR 803; 21 CFR 806; and 21 CFR 807. Revision of the Quality Manual and related procedures will also occur according to your firm. Until your firm establishes and maintains a Quality System and Quality Manual procedures as required by 21 CFR 820.186, and provides a copy of the procedures to the Agency for review, the adequacy of the response cannot be determined.\n\n8. Failure to have sufficient personnel with the necessary education, background, training, and experience to assure that all activities required by this part are correctly performed, as required by 21 CFR 820.25(a). For example, your firm has not demonstrated it had any prior knowledge of U.S. FDA regulations and requirements including 21 CFR Part 820 - Quality System regulation.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your firm described the completion of employee training for 21 CFR 820; 21 CFR 803, 21 CFR 807, 21 CFR 806 and 21 CFR 830. Until your firm can demonstrate adequate employee training for all personnel, related to its Quality System as required by 21 CFR 820.25, and provides a copy of the training for Agency review, the adequacy of the response cannot be determined.\n\nOur inspection also revealed that your firm’s Class II Rigid Nasopharyngoscope devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\nFailure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm states MDR Control procedures will be established, and a complaint retrospective review will be conducted for MDR reportable events. However, the response does not include how the electronic submission of MDR reportable events to the Agency will occur. Until your firm develops, maintains, and implements written MDR procedures as required by 21 CFR 803.17, and provides a copy of the procedures for Agency review, the response is not adequate.\n\nGiven the serious nature of the violations of the Act, Otoscopes, Rigid Laryngoscopes, and Rigid Nasopharyngoscopes manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violations described in this letter. We will notify you regarding the adequacy of your firm’s responses and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review.\n\nIf you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #614851 when replying. If you have any questions about the contents of this letter, please contact Shu-Chen Peng, Ph.D. at (301) 796-6481.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nfor Malvina Eydelman, M.D.\n\nDirector\n\nOHT 1: Office of Ophthalmic, Anesthesia,\n\nRespiratory, ENT and Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","Tianjin Bolang Science-Technology Development Co., Ltd.","tianjin-bolang-science-technology-development-co-ltd-614851-06172021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftianjin-bolang-science-technology-development-co-ltd-614851-06172021","2026-10-26T08:10:12.112649+00:00","2021-08-17","614851","Medical Devices","Mr. Lin Qi","2026-08-20T02:41:21.596+00:00","2021-06-17",{"id":97,"raw":98,"subject":102,"body_html":103,"body_text":104,"firm_name":105,"letter_id":106,"created_at":107,"fei_number":20,"letter_url":108,"updated_at":109,"action_type":23,"case_status":24,"posted_date":110,"marcs_cms_no":111,"product_type":112,"closeout_date":20,"issuing_office":38,"recipient_name":113,"body_fetched_at":114,"delivery_method":115,"recipient_title":20,"reference_number":20,"action_taken_date":116,"medical_device_id":20,"response_letter_date":20},22112,[99,100,101,38,102,13,13,13],"\u003Ctime datetime=\"2026-11-03T05:00:00Z\">11\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-27T04:00:00Z\">10\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fguangzhou-jiugong-research-and-development-biotechnology-co-ltd-737769-10272026\">Guangzhou Jiugong Research And Development Biotechnology Co., Ltd.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Yun Ma\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Product Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Guangzhou Jiugong Research And Development Biotechnology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 3 Yiheng Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nanling Gongye Districtqinghu Ma Tian Street Jiahe Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Baiyun Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangzhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangdong Sheng\u003C\u002Fspan>, \u003Cspan>510000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 27, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-27-13\u003C\u002Fp>\u003Cp>To Mr. Yun Ma:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during review of your drug manufacturing facility, Guangzhou Jiugong Research And Development Biotechnology Co., Ltd., FDA Establishment Identifier (FEI) 3043646847. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>Your facility is registered with the FDA as a manufacturer of over-the-counter (OTC) drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. FDA has reviewed the records submitted from \u003Cstrong>(b)(4)\u003C\u002Fstrong> on your behalf in response to our May 1, 2026, request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>Additionally, the OTC drug product, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” is adulterated under section 501(a)(4)(A) as this drug product bears or contains a color additive that is unsafe within the meaning of section 721 of the FD&amp;C Act, 21 U.S.C. 379e. Accordingly, the introduction or delivery for introduction of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” into interstate commerce is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>Use of Cancelled Color Additive FD&amp;C Red No. 2\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on our review of drug product labels, the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” contains the color additive “CI 16185” (also known as FD&amp;C Red No. 2 or Amaranth). In 1976, FDA cancelled the certification and delisted FD&amp;C Red No. 2 because it could not be proven safe for use. Under 21 CFR 81.30(j)(1), using FD&amp;C Red No. 2 in drugs after January 28, 1976, results in the drug being adulterated.\u003C\u002Fp>\u003Cp>Any color additive not explicitly listed as safe for its intended use is deemed unsafe within the meaning of section 721(a) of the FD&amp;C Act. The inclusion of a delisted color additive in your drug product formulation indicates that your quality unit’s review (as required under 21 CFR 211.22) of your raw material qualification process and formulation review procedures is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The records and information provided demonstrate that the quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of the drug manufacturing operations. The response includes discrepancies between the color additive on the labeling versus the batch formulation spreadsheet versus the color specified in the certificate of analysis (COA). For example, the labeling for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” listed “CI 16185” (also known as the cancelled color FD&amp;C Red No. 2) as the color additive. However, the separate formulation ingredient information provided listed a second color additive \u003Cstrong>(b)(4)\u003C\u002Fstrong> (also known as \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and the COA provided indicated a third distinct color additive, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>On July 28, 2026, the FDA sent an electronic request for additional information requesting clarification of these color additive discrepancies. This request went unanswered as did the follow-up electronic request sent on August 5, 2026.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to, the following:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>A comprehensive assessment of your documentation to ensure you retain accurate records throughout your operation.\u003C\u002Fli>\u003Cli>A list of all products distributed in the United States in the last three years, with lot number, quantity shipped, and expiry dates. Identify the drug products you distributed.\u003C\u002Fli>\u003Cli>A list of your customers and addresses where the drug products were distributed.\u003C\u002Fli>\u003Cli>A copy of your quality agreement with the product owner, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>A risk assessment to review all your drug formulations to ensure the use of appropriate color additives, including any that may use alternate names. For more information, see the webpage for Regulatory Status of Color Additives at https:\u002F\u002Fwww.hfpappexternal.fda.gov\u002Fscripts\u002Ffdcc\u002Findex.cfm?set=ColorAdditives.\u003C\u002Fli>\u003Cli>Your action plan to address any product quality or patient safety risks for batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in U.S. distribution, including customer notifications and recalls or market withdrawals.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Revocation of FD&amp;C Red No. 3\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA revoked the authorization for the use of FD&amp;C Red No. 3. We recommend manufacturers review their drug product formulations. Manufacturers who use FD&amp;C Red No. 3 in ingested drugs will have until January 18, 2028, to reformulate their products. For more information, see https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fhfp-constituent-updates\u002Ffda-revoke-authorization-use-red-no-3-food-and-ingested-drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act (21 U.S.C. 321(i)). Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. We note that under section 301(a) of the FD&amp;C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\u003C\u002Fp>\u003Cp>We also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&amp;C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Guangzhou Jiugong Research And Development Biotechnology Co., Ltd., located at No. 3 Yiheng Road, Nanling Gongye Districtqinghu Ma Tian Street, Jiahe Street, Baiyun District, Guangzhou, Guangdong into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3043646847 and ATTN: Lynnsey Renn in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc:\u003Cbr>FDA Listing\u003Cbr>US agent\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Yun Ma\n\nRecipient Title\n\nProduct Manager\n\nGuangzhou Jiugong Research And Development Biotechnology Co., Ltd.\n\nNo. 3 Yiheng Road\n\nNanling Gongye Districtqinghu Ma Tian Street Jiahe Street\n\nBaiyun Qu\n\nGuangzhou Shi\n\nGuangdong Sheng, 510000\n\nChina\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 27, 2026\nWARNING LETTER\nReference number: 320-27-13\nTo Mr. Yun Ma:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.\nFDA Review\nViolations were identified and documented during review of your drug manufacturing facility, Guangzhou Jiugong Research And Development Biotechnology Co., Ltd., FDA Establishment Identifier (FEI) 3043646847. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nYour facility is registered with the FDA as a manufacturer of over-the-counter (OTC) drug products, including (b)(4). FDA has reviewed the records submitted from (b)(4) on your behalf in response to our May 1, 2026, request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\nAdditionally, the OTC drug product, “(b)(4),” is adulterated under section 501(a)(4)(A) as this drug product bears or contains a color additive that is unsafe within the meaning of section 721 of the FD&C Act, 21 U.S.C. 379e. Accordingly, the introduction or delivery for introduction of “(b)(4)” into interstate commerce is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\nUse of Cancelled Color Additive FD&C Red No. 2\nBased on our review of drug product labels, the “(b)(4)” contains the color additive “CI 16185” (also known as FD&C Red No. 2 or Amaranth). In 1976, FDA cancelled the certification and delisted FD&C Red No. 2 because it could not be proven safe for use. Under 21 CFR 81.30(j)(1), using FD&C Red No. 2 in drugs after January 28, 1976, results in the drug being adulterated.\nAny color additive not explicitly listed as safe for its intended use is deemed unsafe within the meaning of section 721(a) of the FD&C Act. The inclusion of a delisted color additive in your drug product formulation indicates that your quality unit’s review (as required under 21 CFR 211.22) of your raw material qualification process and formulation review procedures is inadequate.\nYour firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nThe records and information provided demonstrate that the quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of the drug manufacturing operations. The response includes discrepancies between the color additive on the labeling versus the batch formulation spreadsheet versus the color specified in the certificate of analysis (COA). For example, the labeling for the “(b)(4)” listed “CI 16185” (also known as the cancelled color FD&C Red No. 2) as the color additive. However, the separate formulation ingredient information provided listed a second color additive (b)(4) (also known as (b)(4)) and the COA provided indicated a third distinct color additive, (b)(4).\nOn July 28, 2026, the FDA sent an electronic request for additional information requesting clarification of these color additive discrepancies. This request went unanswered as did the follow-up electronic request sent on August 5, 2026.\nYour QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to, the following:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nA comprehensive assessment of your documentation to ensure you retain accurate records throughout your operation.\nA list of all products distributed in the United States in the last three years, with lot number, quantity shipped, and expiry dates. Identify the drug products you distributed.\nA list of your customers and addresses where the drug products were distributed.\nA copy of your quality agreement with the product owner, (b)(4).\nA risk assessment to review all your drug formulations to ensure the use of appropriate color additives, including any that may use alternate names. For more information, see the webpage for Regulatory Status of Color Additives at https:\u002F\u002Fwww.hfpappexternal.fda.gov\u002Fscripts\u002Ffdcc\u002Findex.cfm?set=ColorAdditives.\nYour action plan to address any product quality or patient safety risks for batches of (b)(4) in U.S. distribution, including customer notifications and recalls or market withdrawals.\nResponsibilities as a Contractor\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nRevocation of FD&C Red No. 3\nFDA revoked the authorization for the use of FD&C Red No. 3. We recommend manufacturers review their drug product formulations. Manufacturers who use FD&C Red No. 3 in ingested drugs will have until January 18, 2028, to reformulate their products. For more information, see https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fhfp-constituent-updates\u002Ffda-revoke-authorization-use-red-no-3-food-and-ingested-drugs.\nCosmetics Manufactured for Distribution in the United States\nIn addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act (21 U.S.C. 321(i)). Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. We note that under section 301(a) of the FD&C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\nWe also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Guangzhou Jiugong Research And Development Biotechnology Co., Ltd., located at No. 3 Yiheng Road, Nanling Gongye Districtqinghu Ma Tian Street, Jiahe Street, Baiyun District, Guangzhou, Guangdong into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3043646847 and ATTN: Lynnsey Renn in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc:\nFDA Listing\nUS agent\n(b)(4)","Guangzhou Jiugong Research And Development Biotechnology Co., Ltd.","guangzhou-jiugong-research-and-development-biotechnology-co-ltd-737769-10272026","2026-11-10T01:02:16.121874+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fguangzhou-jiugong-research-and-development-biotechnology-co-ltd-737769-10272026","2026-11-17T01:02:03.701861+00:00","2026-11-03","737769","Drugs Over-the-Counter Drugs","Mr. Yun Ma","2026-11-10T01:02:46.154+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-10-27",5,{"510k":119,"classification":120,"enforcement":121,"event":122,"event_backfill":123,"pma":124,"warning_letter":125},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]